Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, has established and invested in its new contract manufacturing services division to bring late-stage clinical assets through to commercialization. Leveraging its extensive manufacturing, process development and logistics expertise, Dendreon now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs.
Dendreon is one of only four companies manufacturing cell therapies for commercial use in the United States and began investing in dedicated capacity for later-stage partner programs within its existing infrastructure in early 2021. The company’s 180,000+ square foot FDA cGMP-certified manufacturing facility in Seal Beach, CA will serve as the contract manufacturing services hub. Its Seattle facility will serve as the process development and manufacturing sciences center.
“We are enabling the future of immunotherapy and supporting an unmet need in the market with immediate access to capacity and expertise,” said Maria Cho, Vice President of Business Development and Corporate Strategy. “We are looking to establish partnerships with biopharmaceutical companies developing CAR-Ts, autologous, or allogeneic cell therapies. Looking ahead, we plan to continue to leverage our core capabilities as a growth engine for our strategic partners and the industry as a whole."